KDR and neoplasm: While exploring the immunological factors involved in the resistance mechanism of high-dose VEGFR2-TKI on tumor progression, we found that the therapeutic target VEGFR2 was expressed at significantly higher levels in T lymphocytes than in myeloid cells (Figure 2A and Supplementary Figure S2C), and γδ T cells exhibited higher VEGFR2 expression than αβ T cells (Figure 2B).